TY - JOUR T1 - Treatment Results of MammoSite Catheter in Combination with Whole-breast Irradiation JF - Anticancer Research JO - Anticancer Res SP - 355 LP - 360 VL - 36 IS - 1 AU - ALEXANDER GITT AU - HUGO BÖSE-RIBEIRO AU - CARSTEN NIEDER AU - PHILIPP GÜNTHER KUP AU - HORST HERMANI AU - HELMUT BÜHLER AU - HASAN YAVUZ ERGÖNENÇ AU - DOROTHEE DRÜPPEL AU - IRENÄUS ANTON ADAMIETZ AU - KHASHAYAR FAKHRIAN Y1 - 2016/01/01 UR - http://ar.iiarjournals.org/content/36/1/355.abstract N2 - Aim. To report the initial outcomes of patients treated with the MammoSite brachytherapy device (MSBT) as a boost followed by external whole-breast irradiation (WBI). Patients and Methods: From June 2011 to March 2014, 107 patients (typically with pT1-2, pN0-1, M0 disease) were treated with breast-conserving therapy and adjuvant radiotherapy with MSBT (15 Gy in 2.5-Gy fractions) followed by WBI (median=50.4 Gy). Toxicity was classified according to the Common Terminology Criteria for Adverse Events v3.0. The median follow-up was 21 months. Results: To date, no ipsilateral breast-tumor recurrences have been observed; 102 patients (95%) were alive at last follow-up. Two patients (2%) developed distant metastases. Five patients (5%) died during follow-up, only one as a result of breast cancer. The 2-year disease-free survival was 95±3%. The incidence of asymptomatic and symptomatic seroma in 90 days after MSBT was 28% and 10%, respectively. Infectious mastitis was observed in three patients (3%), who were treated successfully with antibiotics. Only three patients (3%) developed RT-induced dermatitis greater than grade 2 after WBI. Conclusion: The boost technique used in this study seems to provide excellent local control with acceptable toxicity, similar to the results observed with other forms of interstitial accelerated partial-breast irradiation as a boost. Long-term follow-up is necessary to refine the patient selection criteria and to assess efficacy and late toxicities. ER -